Skip to Primary Navigation

Skip to main content

Elanco fined $15m for Reg S-K misrepresentations

Multicolor files in a clinic drawer
Photo: Linda Raymond/Getty Images

Alexander Barzacanos

1 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

Elanco’s use of sales incentives created misleading impressions of customer demand, the SEC stated.

Elanco, a veterinary pharmacology company, agreed to settle charges with the SEC over accusations that it made misleading statements about its revenue growth and user demand. The company will pay a $15m penalty without admitting or denying the charges.  

The SEC’s charges arise from deficiencies in Elanco’s

, , , , , , , , , , ,

Subscribe to continue reading

Subscribe to our Premium plan for full access to every article like this one, plus exclusive interviews, podcasts, and more.

Subscribe

Already have Premium? Sign in